This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Conflicted on These Healthcare Names: Tenaya Therapeutics (TNYA), IN8bio (INAB) and Veeva Systems (VEEV)

Tipranks - Tipranks - Fri Jun 5, 6:04AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Tenaya Therapeutics (TNYA), IN8bio (INAB) and Veeva Systems (VEEV).

Claim 55% Off TipRanks

Tenaya Therapeutics (TNYA)

In a report released yesterday, Michael Ulz from Morgan Stanley reiterated a Buy rating on Tenaya Therapeutics, with a price target of $2.00. The company’s shares closed last Wednesday at $0.79, close to its 52-week low of $0.39.

According to TipRanks.com, Ulz is a 2-star analyst with an average return of 0.3% and a 41.0% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Aardvark Therapeutics, Inc., Kyverna Therapeutics, Inc., and Arrowhead Pharmaceuticals. ;'>

Currently, the analyst consensus on Tenaya Therapeutics is a Strong Buy with an average price target of $10.33, an 1101.2% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $3.00 price target.

See the top stocks recommended by analysts >>

IN8bio (INAB)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on IN8bio, with a price target of $6.00. The company’s shares closed last Wednesday at $1.54, close to its 52-week high of $1.74.

According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of 13.5% and a 41.5% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Actuate Therapeutics, Inc., Unicycive Therapeutics, and Janux Therapeutics Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for IN8bio with a $5.00 average price target, a 220.5% upside from current levels. In a report issued on May 22, JonesTrading also maintained a Buy rating on the stock with a $5.00 price target.

Veeva Systems (VEEV)

Morgan Stanley analyst Craig Hettenbach maintained a Hold rating on Veeva Systems today and set a price target of $215.00. The company’s shares closed last Wednesday at $178.72, close to its 52-week low of $170.25.

According to TipRanks.com, Hettenbach is ranked #2602 out of 12292 analysts.

Currently, the analyst consensus on Veeva Systems is a Moderate Buy with an average price target of $253.67, representing a 39.8% upside. In a report issued on May 20, TipRanks – xAI also downgraded the stock to Hold with a $178.00 price target.

Read More on TNYA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).